Core Points - The release of the "dual directory" system for basic medical insurance and commercial health insurance marks a new phase in China's healthcare reform, emphasizing precision, differentiation, and collaboration in the medical insurance system [1][15][16] - The updated basic medical insurance directory will be implemented nationwide starting January 1, 2026, adding 114 new drugs, including 50 innovative drugs, while removing 29 drugs that are clinically unavailable or can be better replaced [1][15][16] - The first edition of the commercial health insurance innovative drug directory focuses on 19 high-innovation, high-clinical-value drugs that exceed the basic insurance coverage, including CAR-T cell therapy and treatments for rare diseases [1][15][16] Group 1: Key Signals - Signal 1: Balancing "Basic Protection" and "Promoting Innovation" - The adjustment of the medical insurance drug directory reflects a dual consideration of the sustainability of the insurance fund and fairness in drug access for patients, with a focus on encouraging innovation and optimizing the structure [4][17][19] - The overall success rate of the newly added innovative drugs is 88%, an increase from 76% in 2024, indicating a shift towards strategic purchasing and value-based purchasing in medical insurance [4][17][19] Group 2: Commercial Health Insurance Directory - Signal 2: Addressing the "Beyond Insurance" Drug Dilemma - The commercial health insurance innovative drug directory serves as an upgrade package to meet higher-level medical needs, filling the gap left by basic insurance, which cannot cover all high-value innovative drugs [6][9][20] - The establishment of this directory provides a systematic recommendation of innovative drugs for commercial insurance companies, avoiding confusion and inconsistency in standards [6][9][20] Group 3: Implementation and Coordination - Signal 3: Strengthening System Coordination and Clinical Connection - The implementation of the dual directory requires a comprehensive approach involving information system transitions, hospital management, payment mechanism restructuring, and patient awareness [10][23][24] - The policy mandates a nationwide switch to the new directory by January 1, 2026, with a six-month transition period for drugs removed from the directory to ensure continuity of patient care [10][24][26] - The commercial health insurance directory's drugs will follow similar procurement and usage guidelines as those under basic insurance, facilitating access to innovative treatments [10][27][28]